Placeholder Banner

BIO Submits Comments re: CY 2020 Medicare Physician Fee Schedule Proposed Rule

October 21, 2019

Dear Administrator Verma:

The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment
on the Center for Medicare and Medicaid Services’ (CMS’s) CY2020 Revisions to Payment
Policies under the Physician Fee Schedule (PFS) and Other Changes to Part B Payment
Policies (“Proposed Rule”).

BIO is the world’s largest trade association representing biotechnology companies, academic
institutions, state biotechnology centers and related organizations across the United States
and in more than 30 other nations. BIO’s members develop medical products and
technologies to treat patients afflicted with serious diseases, to delay the onset of these
diseases, or to prevent them in the first place. In that way, our members’ novel
therapeutics, vaccines, and diagnostics not only have improved health outcomes, but also
have reduced healthcare expenditures due to fewer physician office visits, hospitalizations,
and surgical interventions. BIO membership includes biologics and vaccine manufacturers
and developers who have worked closely with stakeholders across the spectrum, including
the public health and advocacy communities, to support policies that help ensure access to
innovative and life-saving medicines and vaccines for all individuals.

We offer comments on the following areas in the proposed rule, with an emphasis on
ensuring that Medicare beneficiaries have access to the full range of items and services
necessary to their health:

• BIO appreciates the opportunity to comment on the agency’s future consideration of
bundled payments under the PFS but urges CMS to prioritize patient access to
appropriate therapies and to weigh the results of other demonstrations underway
rather than attempting to swiftly implement bundled payments.
• BIO supports the proposal to retain more granular payments for Evaluation and
Management (E/M) services, which we think will support access to appropriate care
for the sickest patients.​

Discover More
On November 9, BIO submitted comments on the FDA Draft Guidance, Drug-Drug Interaction Assessment for Therapeutic Proteins. In the comments, BIO thanks the FDA for the opportunity to submit comments but requests that the Guidance include a…
On August 6, BIO submitted comments on the NMPA Draft Technical Guideline on Clinical Trials of Cellular Immunotherapy Products. In the comments, BIO thanks NMPA for the opportunity to submit comments but argues for a more robust commenting period…
October 30, 2020 Re: Docket No. FDA–2020-D-1564: FDA Draft Guidance, Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation. Dear Sir/Madam: The Biotechnology…